A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Run by AstraZeneca · NCT05629585 · Data updated 2026-11-12
Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2027-09-01.
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 130 Years |
| Sex | All |
| Enrollment | 1174 (actual) |
| Sponsor | AstraZeneca Industry-sponsored |
| Drugs / interventions | Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab |
| Locations | 276 sites (Belgium, Brazil, Canada, China, Denmark, France, Germany, Greece and more) |
| Trial ID | NCT05629585 on ClinicalTrials.gov |
What this trial studies
The study will investigate the efficacy and safety of Dato-DXd with or without durvalumab when compared with ICT (capecitabine and/or pembrolizumab) in participants with stage I to III TNBC who have residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy. The primary objective of the study is to demonstrate superiority of Dato-DXd in combination with durvalumab relative to ICT by assessment of iDFS in participants with stage I to III TNBC with residual invasive disease at surgical resection following neoadjuvant therapy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participant must be ≥ 18 years at the time of screening. 2. Histologically confirmed invasive TNBC, as defined by the ASCO/CAP guidelines. 3. Residual invasive disease in the breast and/or axillary lymph node(s) at surgical resection following neoadjuvant therapy. 4. Completed at least 6 cycles of neoadjuvant therapy containing an anthracycline and/or a taxane with or without platinum chemotherapy, with or without pembrolizumab. 5. No evidence of locoregional or distant relapse. 6. Surgical removal of all clinically evident disease in the breast and lymph nodes. 7. ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to randomisation. 8. All participants must provide an FFPE tumour sample from residual invasive disease at surgery for tissue-based analysis. 9. No adjuvant systemic therapy. 10. Radiotherapy (if indicated) delivered before the start of study intervention. 11. If post-operative radiation therapy is given, an interval of no more than 6 weeks between the completion of radiation therapy and the date of randomisation (radiation therapy can be completed during screening period). If no post-operative radiation therapy is given, an interval of no more than 16 weeks between the date of breast surgery and the date of randomisation. 12. Has LVEF ≥ 50% by either an ECHO or MUGA scan within 28 days before randomisation. 13. Eligible for one of the therapy options listed as investigator's choice per investigator assessment. 14. No known germline BRCA1 or BRCA2 pathogenic mutation. 15. Adequate bone marrow reserve and organ function within 7 days before randomisation. Exclusion Criteria: 1. Stage IV (metastatic) TNBC. 2. History of prior invasive breast cancer, or evidence of recurrent disease following preoperative therapy and surgery. 3. Severe or uncontrolled medical conditions including systemic diseases, history of allogeneic organ transplant and active bleeding diseases, ongoing or active infection, serious chronic gastrointestinal conditions associated with diarrhea chronic diverticulitis or previous complicated diverticulitis. 4. History of another primary malignancy except for adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ disease (including ductal carcinoma in situ) that has undergone potentially curative therapy, or other solid malignancy treated with curative intent with no known active disease within 5 years before randomisation and of low potential risk for recurrence. 5. Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss). 6. Active or prior documented autoimmune or inflammatory disorders. 7. Clinically significant corneal disease. 8. Active or uncontrolled hepatitis B or C virus infection. 9. Known HIV infection that is not well controlled 10. Active tuberculosis infection. 11. Mean resting corrected QTcF \> 470 ms regardless of gender, obtained from triplicate 12-lead ECGs performed at screening. 12. Uncontrolled or significant cardiac disease. 13. History of non-infectious ILD/pneumonitis including radiation, pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. 14. Has severe pulmonary function compromise. 15. Any known active liver disease. 16. Grade ≥ 2 peripheral neuropathy of any aetiology. 17. Prior exposure to a PD-1/PD-L1 inhibitor other than pembrolizumab. 18. Current or prior use of immunosuppressive medication within 14 days prior to randomisation. 19. Participants with a known severe hypersensitivity to Dato-DXd or any of the excipients of these products including but not limited to polysorbate 80 or other monoclonal antibodies. 20. Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors. 21. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to randomisation, randomisation into a prior Dato-DXd, T-DXd, or durvalumab study regardless of treatment assignment. 22. Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.
Where it's running
-
Research Site
Gilbert, Arizona, United States -
Research Site
Tucson, Arizona, United States -
Research Site
Tucson, Arizona, United States -
Research Site
Hot Springs, Arkansas, United States -
Research Site
Little Rock, Arkansas, United States -
Research Site
Springdale, Arkansas, United States
Show 44 more locations
-
Research Site
Beverly Hills, California, United States -
Research Site
Costa Mesa, California, United States -
Research Site
Duarte, California, United States -
Research Site
Fountain Valley, California, United States -
Research Site
Irvine, California, United States -
Research Site
La Jolla, California, United States -
Research Site
Lakewood, California, United States -
Research Site
Los Angeles, California, United States -
Research Site
Los Angeles, California, United States -
Research Site
Newport Beach, California, United States -
Research Site
Newport Beach, California, United States -
Research Site
Orange, California, United States -
Research Site
Roseville, California, United States -
Research Site
Upland, California, United States -
Research Site
Vallejo, California, United States -
Research Site
Denver, Colorado, United States -
Research Site
New Haven, Connecticut, United States -
Research Site
Newark, Delaware, United States -
Research Site
Washington D.C., District of Columbia, United States -
Research Site
Altamonte Springs, Florida, United States -
Research Site
Hollywood, Florida, United States -
Research Site
Miami Beach, Florida, United States -
Research Site
Tallahassee, Florida, United States -
Research Site
West Palm Beach, Florida, United States -
Research Site
Athens, Georgia, United States -
Research Site
Atlanta, Georgia, United States -
Research Site
Atlanta, Georgia, United States -
Research Site
Chicago, Illinois, United States -
Research Site
Maywood, Illinois, United States -
Research Site
Westwood, Kansas, United States -
Research Site
Lexington, Kentucky, United States -
Research Site
Louisville, Kentucky, United States -
Research Site
Louisville, Kentucky, United States -
Research Site
Louisville, Kentucky, United States -
Research Site
New Orleans, Louisiana, United States -
Research Site
Annapolis, Maryland, United States -
Research Site
Baltimore, Maryland, United States -
Research Site
Columbia, Maryland, United States -
Research Site
Boston, Massachusetts, United States -
Research Site
Detroit, Michigan, United States -
Research Site
St Louis, Missouri, United States -
Research Site
Camden, New Jersey, United States -
Research Site
Albuquerque, New Mexico, United States -
Research Site
New York, New York, United States
+226 more sites. See ClinicalTrials.gov for the full list.
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Durvalumab with FLOT before and after surgery for resectable gastric/GEJ cancer in Chinese patients
This trial tests whether adding durvalumab to FLOT chemotherapy before and after surgery helps Chinese patients with resectable gastric or gastroesophageal junction cancer.
-
Zolbetuximab added to FLOT and durvalumab before surgery for CLDN18.2-positive gastric/GEJ cancer
This study tests whether adding zolbetuximab to FLOT chemotherapy plus durvalumab can improve tumor response before surgery in adults with CLDN18.2-positive gastric or GEJ cancer.
-
Alternating chemo-immunotherapy and FGFR inhibitor for FGFR-positive biliary tract cancer
This phase 2 trial tests whether alternating gemcitabine/cisplatin with durvalumab and the FGFR2 inhibitor pemigatinib can help people with unresectable or metastatic biliary tract cancers that have FGFR alterations.
-
Durvalumab plus histotripsy for intrahepatic cholangiocarcinoma
This study tests whether adding histotripsy to ongoing durvalumab helps people with advanced intrahepatic cholangiocarcinoma by boosting the immune response and checking safety.
-
Futibatinib and immunotherapy with chemo as first-line treatment for advanced biliary tract cancer
A first-line treatment test combines Futibatinib with Zimberelimab and Gemcitabine/Cisplatin to see if it improves survival in people with unresectable or advanced biliary tract cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.